AstraZeneca already produces an adenoviral vector Covid-19 vaccine, and emphasized the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programs beyond the coronavirus pandemic.
AstraZeneca already produces an adenoviral vector Covid-19 vaccine, and emphasized the potential of the self-amplifying RNA (saRNA) technology in novel therapeutic programs beyond the coronavirus pandemic.